Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease
- 28 May 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (5), 1753-1769
- https://doi.org/10.1021/jm400164c
Abstract
HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a P1/P1′ acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.Keywords
This publication has 45 references indexed in Scilit:
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectivesGut, 2012
- Novel Therapies for Hepatitis C: Insights from the Structure of the VirusAnnual Review of Medicine, 2012
- Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-PolymeraseJournal of Medicinal Chemistry, 2011
- Introduction: A smouldering public-health crisisNature, 2011
- Directly acting antivirals against hepatitis C virusJournal of Antimicrobial Chemotherapy, 2011
- Daclatasvir dihydrochlorideDrugs of the Future, 2011
- Development of novel therapies for hepatitis CAntiviral Research, 2010
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001